PDCD1LG2 and neoplasm: However, during anti‐PD‐1 therapy, PD‐L2+ EV‐mediated T‐cell inhibition can be effectively blocked by the antibody, resulting in a significant reduction in tumour size compared to tumours without PD‐L2+ EVs.